Toxicity and feasibility analysis for cisplatin-based concomitant chemoradiotherapy in locally advanced nasopharyngeal carcinoma

Journal of B.U.ON.

Volumn 13, Issue 1, 2008, Pages 43-50

  Atasoy, Beste M ^a   Dane, F ^a   Yumuk, P F ^a   Akgun Z ^a   Turhal, N S ^a   Abacioglu U ^a   Sengoz M ^b  

^a MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b Acibadem Kozyatagi Hospital   (Turkey)

Author keywords

Cisplatin; Concurrent chemoradiotherapy; Nasopharyngeal cancer; Toxicity

Indexed keywords

CISPLATIN; DEXAMETHASONE; DOCETAXEL; FLUOROURACIL; HEMOGLOBIN; SEROTONIN ANTAGONIST;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DERMATITIS; DISEASE FREE SURVIVAL; DYSPHAGIA; FATIGUE; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOTHYROIDISM; KARNOFSKY PERFORMANCE STATUS; LARYNX DISORDER; MALE; MULTIPLE CYCLE TREATMENT; NASOPHARYNX CARCINOMA; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHARYNX DISEASE; RADIATION DERMATITIS; RETROSPECTIVE STUDY; SIDE EFFECT; STOMATITIS; SURVIVAL RATE; TASTE; TASTE DISORDER; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MALE; MIDDLE AGED; MUCOSITIS; NASOPHARYNGEAL NEOPLASMS;

EID: 41549156129     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Baujat B, Audry H, Bourhis J et al. MAC-NPC Collaborative Group. Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients. lnt J Radiat Oncol Biol Phys 2006; 64: 47-56.
2. Al-Sarraf M, LeBlanc M, Giri PG et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 1998; 16: 1310-1317.
3. Al-Sarraf M, LeBlanc M, Giri PG et al. Superiority of five year survival with chemo-radiotherapy vs radiotherapy in patients with locally advanced nasopharyngeal cancer: Intergroup (0099) (SWOG 8892, RTOG 8817, ECOG 2388) Phase III study; Final Report. Proc Am Soc Clin Oncol 2001; 20: 227 (abstr).
4. Lin JC, Jan JS, Hsu CY et al. Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: Positive effect on overall and progression-free survival. J Clin Oncol 2003; 21: 631-637.
5. Lee AW, Lau WH, Tung SY et al. Hong Kong Nasopharyngeal Cancer Study Group. Preliminary Results of a Randomized Study on Therapeutic Gain by Concurrent Chemotherapy for Regionally-Advanced Nasopharyngeal Carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group. J Clin Oncol 2005; 23: 6966-6975.
6. Chan AT, Teo PM, Ngan RK et al. Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal. carcinoma: progression-free survival analysis of a phase III randomized trial. J Clin Oncol 2002; 20: 2038-2044.
7. Wee J, Tan EH, Tai BC et al. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union Against Cancer stage III and IV nasopharyngeal cancer of the endemic variety. J Clin Oncol 2005; 23: 6730-6738.
8. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
9. Trotti A. Toxicity in Head and Neck Cancer: A Review of Trends and Issues. Int J Radiat Oncol Biol Phys 2000; 47: 1-12.
10. Benasso M, Bonelli L, Numico G et al. Treatment with cisplatin and fluorouracil alternating with radiation favourably affects prognosis of inoperable squamous cell carcinoma of the head and neck: results of a multivariate analysis on 273 patients. Ann Oncol 1997; 8: 773-779.
11. Deleo VA, Taylor SC, Belsito DV et al. Randomized comparison of induction cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancer. J Clin Oncol 1994; 12: 385-395.
12. Trotti A, Bellm LA, Epstein JB et al. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systemic literature review. Radiat Oncol 2003; 66: 253-262.
13. Chen MK, Lee HS, Chang CC. Primary tumour volume: important predictor of outcome for T3- and T4-staged nasopharyngeal carcinoma. J Otolaryngol 2004; 33: 254-257.
14. Mangar S, Sleviri N, Mais K et al. Evaluating predictive factors for determining enteral nutrition in patients receiving radical radiotherapy for head and neck cancer: A retrospective review. Radiat Oncol 2006; 78: 152-158.
15. Stiller CA. International patterns of cancer incidence in adolescents. Cancer Treat Rev 2007 (in press).
16. Erkal HS, Serin M, Cakmak A. Nasopharyngeal carcinomas: analysis of patient, tumor and treatment characteristics determining outcome. Radiat Oncol 2001; 61: 247-256.
17. Ozyar E. Gurkaynak M, Yildiz F et at. Non-metastatic stage IV nasopharyngeal carcinoma patients: analysis of the pattern of relapse and survival. Radiat Oncol 2004; 72: 71-77.
18. Teo PM, Chan AT, Lee WY et al. Enhancement of local control in locally advanced node-positive nasopharyngeal carcinoma by adjunctive chemotherapy. Int J Radiat Oncol Biol Phys 1999; 43: 261-271.
19. Chua DT, Ma J, Sham JS et al. Long-term survival after cisplatin-based induction chemotherapy and radiotherapy for nasopharyngeal carcinoma: a pooled data analysis of two phase III trials. J Clin Oncol 2005; 23: 1118-1124.
20. Lin JC, Liang WM, Jan JS et al. Another way to estimate outcome of advanced nasopharyngeal carcinoma-is concurrent chemoradiotherapy adequate? Int J Radiat Oncol Biol Phys 2004; 60: 156-164.
21. Chajón EA, Garcia-Berrocal MI, De la Fuente C etal. Toxicity and compliance with a chemoradiotherapy schedule for advanced nasopharyngeal carcinoma: A single institution experience using the Intergroup 0099 study regimen. Acta Oncol 2005; 44: 85-86.